NYSE:LLYPharmaceuticals
Eli Lilly Uses GLP 1 Cash Flows To Pursue Next Wave RNA Therapies
Eli Lilly (NYSE:LLY) announced an agreement to acquire Orna Therapeutics, a company focused on circular RNA based medicines.
The deal brings Orna's in vivo cell therapy and genetic medicine platform into Lilly's pipeline of drug development programs.
The transaction is framed as an expansion beyond Lilly's existing obesity and diabetes franchise into autoimmune and genetic disease treatment research.
For you as an investor, this move adds a new angle to the NYSE:LLY story, which many people...